CRH Medical (CRM) Earning Somewhat Positive Press Coverage, Report Finds

News articles about CRH Medical (CVE:CRM) have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CRH Medical earned a media sentiment score of 1.44 on their scale. InfoTrie also assigned news stories about the company an news buzz score of 1 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

CRH Medical has a fifty-two week low of C$83.00 and a fifty-two week high of C$128.87.

TRADEMARK VIOLATION NOTICE: “CRH Medical (CRM) Earning Somewhat Positive Press Coverage, Report Finds” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/12/02/crh-medical-crm-earning-somewhat-positive-press-coverage-report-finds.html.

About CRH Medical

CRH Medical Corporation (CRH) specializes in the distribution of medical products directly to physicians, particularly those in the gastroenterologist community. The Company’s lead product, the CRH O’Regan System, is a single use, disposable, hemorrhoid treatment that is used in treating hemorrhoid grades I-IV.

Featured Article: Momentum Indicator: Relative Strength Index

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit